129 related articles for article (PubMed ID: 21156962)
1. Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer.
Weidle UH; Klostermann S; Eggle D; Krüger A
Cancer Genomics Proteomics; 2010; 7(6):287-302. PubMed ID: 21156962
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
3. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.
Strassmann G; Fong M; Freter CE; Windsor S; D'Alessandro F; Nordan RP
J Clin Invest; 1993 Nov; 92(5):2152-9. PubMed ID: 8227330
[TBL] [Abstract][Full Text] [Related]
4. IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells.
Lissat A; Joerschke M; Shinde DA; Braunschweig T; Meier A; Makowska A; Bortnick R; Henneke P; Herget G; Gorr TA; Kontny U
BMC Cancer; 2015 Jul; 15():552. PubMed ID: 26215971
[TBL] [Abstract][Full Text] [Related]
5. [Specific cytotoxicity of recombinant interleukin 6-pseudomonas exotoxin fusion protein (IL6-PE40) on LT12 leukemic cells expressing high levels of interleukin 6 receptor (IL6R)].
Xi YZ
Zhonghua Zhong Liu Za Zhi; 1993 Nov; 15(6):419-22. PubMed ID: 8200278
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils.
Chalaris A; Rabe B; Paliga K; Lange H; Laskay T; Fielding CA; Jones SA; Rose-John S; Scheller J
Blood; 2007 Sep; 110(6):1748-55. PubMed ID: 17567983
[TBL] [Abstract][Full Text] [Related]
7. IL6 receptor
Wosiski-Kuhn M; Robinson M; Strupe J; Arounleut P; Martin M; Caress J; Cartwright M; Bowser R; Cudkowicz M; Langefeld C; Hawkins GA; Milligan C
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):e631. PubMed ID: 31611269
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 and its receptor in cancer: implications for translational therapeutics.
Hong DS; Angelo LS; Kurzrock R
Cancer; 2007 Nov; 110(9):1911-28. PubMed ID: 17849470
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors.
Eliopoulos AG; Stack M; Dawson CW; Kaye KM; Hodgkin L; Sihota S; Rowe M; Young LS
Oncogene; 1997 Jun; 14(24):2899-916. PubMed ID: 9205097
[TBL] [Abstract][Full Text] [Related]
10. NFAT1-regulated IL6 signalling contributes to aggressive phenotypes of glioma.
Jiang Y; Han S; Cheng W; Wang Z; Wu A
Cell Commun Signal; 2017 Dec; 15(1):54. PubMed ID: 29258522
[TBL] [Abstract][Full Text] [Related]
11. Minimal role for STAT1 in interleukin-6 signaling and actions in the murine brain.
Sanz E; Hofer MJ; Unzeta M; Campbell IL
Glia; 2008 Jan; 56(2):190-9. PubMed ID: 18023015
[TBL] [Abstract][Full Text] [Related]
12. Expression of the murine interleukin 6 receptor in hepatoma cells: the intracytoplasmic domain is not required for interleukin 6 signal transduction.
Fiorillo MT; Toniatti C; Van Snick J; Ciliberto G
Eur J Immunol; 1992 Mar; 22(3):799-804. PubMed ID: 1312474
[TBL] [Abstract][Full Text] [Related]
13. The biology of interleukin-6 in the 21st century.
Rose-John S
Semin Immunol; 2014 Feb; 26(1):1. PubMed ID: 24556601
[No Abstract] [Full Text] [Related]
14. IL-6 signal transduction and its physiological roles: the signal orchestration model.
Kamimura D; Ishihara K; Hirano T
Rev Physiol Biochem Pharmacol; 2003; 149():1-38. PubMed ID: 12687404
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 as a therapeutic target.
Rossi JF; Lu ZY; Jourdan M; Klein B
Clin Cancer Res; 2015 Mar; 21(6):1248-57. PubMed ID: 25589616
[TBL] [Abstract][Full Text] [Related]
16. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells.
Halimi H; Eisenstein M; Oh JW; Revel M; Chebath J
Eur Cytokine Netw; 1995; 6(3):135-43. PubMed ID: 8589270
[TBL] [Abstract][Full Text] [Related]
17. Anti-interleukin 6 receptor antibody treatment in rheumatic disease.
Nishimoto N; Kishimoto T; Yoshizaki K
Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i21-7. PubMed ID: 11053081
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease.
Schreiber S; Aden K; Bernardes JP; Conrad C; Tran F; Höper H; Volk V; Mishra N; Blase JI; Nikolaus S; Bethge J; Kühbacher T; Röcken C; Chen M; Cottingham I; Petri N; Rasmussen BB; Lokau J; Lenk L; Garbers C; Feuerhake F; Rose-John S; Waetzig GH; Rosenstiel P
Gastroenterology; 2021 Jun; 160(7):2354-2366.e11. PubMed ID: 33667488
[TBL] [Abstract][Full Text] [Related]
19. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft.
Tamura S; Ouchi KF; Mori K; Endo M; Matsumoto T; Eda H; Tanaka Y; Ishitsuka H; Tokita H; Yamaguchi K
Clin Cancer Res; 1995 Nov; 1(11):1353-8. PubMed ID: 9815931
[TBL] [Abstract][Full Text] [Related]
20. Reversal of some viral IL-6 electrostatic properties compared to IL-6 contributes to a loss of alpha receptor component recruitment.
Perret D; Rousseau F; Tran V; Gascan H
Proteins; 2005 Jul; 60(1):14-26. PubMed ID: 15861391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
